Concepedia
Statistics
Publications
3
Citations
360
H-Index
Active since
2007
Affiliations
Heidelberg University(Current)
German Cancer Research Center
University Hospital Heidelberg
Eli Lilly (United States)
Michael Lahn is an author at Heidelberg University specializing in medicine, cancer pharmacology, and molecular oncology.
Publications per year
2007–2012
Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice
L. Buéno, Dinesh P. de Alwis, Celine Pitou et al. · European Journal of Cancer · 2007 · 202 citations
Medicine, Oncology, Pharmacology +15
LY2109761 Attenuates Radiation-Induced Pulmonary Murine Fibrosis via Reversal of TGF-β and BMP-Associated Proinflammatory and Proangiogenic Signals
Paul Flechsig, Monika Dadrich, Sebastian Bickelhaupt et al. · Clinical Cancer Research · 2012 · 146 citations
Medicine, Oncology, Radiation Oncology +17
Translating the combination of TGFβ blockade and radiotherapy into clinical development in glioblastoma
Mengxian Zhang, Michael Lahn, Peter E. Huber · OncoImmunology · 2012 · 12 citations · Full text
1–3 of 3